Tesamorelin 10 mg + Ipamorelin 3 mg — 13 mg – GHRH / GHS-R Dual Pathway

This research blend combines two growth hormone–axis peptides in a single lyophilized vial: tesamorelin and ipamorelin. The formulation pairs a stabilized GHRH receptor agonist with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation. Tesamorelin is a synthetic 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus and an extended plasma half-life, FDA-approved as Egrifta® for visceral adipose tissue reduction in HIV-associated lipodystrophy. Ipamorelin is a selective pentapeptide GHS-R1a agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways. The 13 mg blend (10 mg Tesamorelin + 3 mg Ipamorelin) is intended as a comparative pharmacology research blend for investigators studying paired GHRH and GHS-R pathway signaling in preclinical models of body composition, growth hormone dynamics, and metabolic endpoints.

Benefits (Research Focus)

• Combined GHRH + GHS-R activation — studied for paired pathway stimulation of the somatotropic axis

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release in research models

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Visceral adipose research — examined for VAT-specific endpoints via the tesamorelin component in lipodystrophy models

• Hormone selectivity — researched for ipamorelin’s reported minimal off-target effects on cortisol, prolactin, and ACTH